What I would add is that as you build out the pharmaceutical supply chain, I think we probably don't speak enough, as an industry, about building out capability in the market. As you develop API resources in the market domestically, you also develop broader international supply chains so that you end up having sourcing hubs around the world globally. As you build that expertise, you are able to utilize that global network.
It's a complicated supply chain. You're not going to fix it overnight. However, what you can do through investment is start to build in-market resourcing, which then strengthens the supply chain, as I mentioned, globally. It's important to have those resources here domestically, the scientific staff, etc., and engineering that's required on this side of the industry.